HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

L Biganzoli Selected Research

Disease Progression

1/2018Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
1/2012First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
3/2011First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
9/2003Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
2/2000Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


L Biganzoli Research Topics

Disease

31Breast Neoplasms (Breast Cancer)
01/2018 - 02/2000
9Neoplasms (Cancer)
11/2015 - 02/2000
5Disease Progression
01/2018 - 02/2000
4Febrile Neutropenia
12/2017 - 11/2001
3Neoplasm Metastasis (Metastasis)
02/2016 - 06/2003
3Neutropenia
11/2003 - 11/2001
2Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
12/2019 - 04/2019
2Cardiotoxicity
01/2017 - 10/2010
2Cardiovascular Diseases (Cardiovascular Disease)
02/2016 - 06/2002
2Hypertension (High Blood Pressure)
01/2012 - 03/2011
2Infections
02/2005 - 11/2003
2Inflammatory Breast Neoplasms
06/2003 - 11/2001
1Rare Diseases (Rare Disease)
04/2019
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2015
1Lung Neoplasms (Lung Cancer)
11/2015
1Colorectal Neoplasms (Colorectal Cancer)
11/2015
1Brain Neoplasms (Brain Tumor)
07/2015
1Infertility (Sterility)
09/2013
1Long Term Adverse Effects
09/2013
1Primary Ovarian Insufficiency
09/2013
1Venous Thromboembolism
03/2011
1Proteinuria
03/2011
1Hemorrhage
03/2011
1Coronary Artery Disease (Coronary Atherosclerosis)
02/2004
1Non-Hodgkin Lymphoma (Lymphosarcoma)
11/2003
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
11/2003
1Flushing
09/2003
1Edema (Dropsy)
09/2003
1Dyspnea (Shortness of Breath)
09/2003
1Nausea
09/2003
1Pulmonary Embolism
09/2003
1Stomatitis
04/2002
1Thrombosis (Thrombus)
04/2002
1Thrombocytopenia (Thrombopenia)
11/2001
1Alopecia (Baldness)
11/2001

Drug/Important Bio-Agent (IBA)

10AnthracyclinesIBA
02/2016 - 04/2000
8Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2017 - 04/2000
7Doxorubicin (Adriamycin)FDA LinkGeneric
12/2017 - 02/2000
6Paclitaxel (Taxol)FDA LinkGeneric
02/2016 - 02/2000
5Taxoids (Taxanes)IBA
02/2016 - 04/2000
4Docetaxel (Taxotere)FDA Link
12/2017 - 03/2013
4Trastuzumab (Herceptin)FDA Link
01/2017 - 10/2010
4Fluorouracil (Carac)FDA LinkGeneric
11/2015 - 11/2001
3Capecitabine (Xeloda)FDA Link
11/2015 - 06/2003
3Epirubicin (Ellence)FDA LinkGeneric
10/2013 - 11/2001
3TamoxifenFDA LinkGeneric
02/2004 - 09/2000
3exemestane (Aromasin)FDA Link
02/2004 - 09/2000
3Hormones (Hormone)IBA
02/2004 - 09/2000
2Carboplatin (JM8)FDA LinkGeneric
11/2015 - 11/2001
2Cisplatin (Platino)FDA LinkGeneric
11/2015 - 11/2001
2N,N'-bis(4-azidobenzoyl)cystineIBA
10/2014 - 10/2014
2Bevacizumab (Avastin)FDA Link
01/2012 - 03/2011
2taxaneIBA
03/2011 - 11/2003
2Biological ProductsIBA
12/2007 - 02/2004
2liposomal doxorubicin (Doxil)FDA Link
05/2006 - 06/2002
2Colony-Stimulating Factors (Colony Stimulating Factor)IBA
02/2005 - 11/2003
2thiamine triphosphorate (TTP)IBA
11/2003 - 09/2000
1palbociclibIBA
01/2018
1Estrogen ReceptorsIBA
01/2018
1Anti-Bacterial Agents (Antibiotics)IBA
12/2017
1AntigensIBA
01/2017
1Vinorelbine (Navelbine)FDA LinkGeneric
11/2015
1PlatinumIBA
11/2015
1Lapatinib (GW572016)FDA Link
07/2015
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
09/2013
1Epidermal Growth Factor (EGF)IBA
01/2012
1human ERBB2 proteinIBA
03/2011
1Aromatase InhibitorsIBA
02/2004
1LipidsIBA
02/2004
1Aromatase (CYP19)IBA
02/2004
1E 25 (E-25)IBA
02/2004
1CholesterolIBA
02/2004
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2003
1Cytotoxins (Cytolysins)IBA
11/2003
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
06/2002
1GemcitabineFDA Link
04/2002
1Transaminases (Aminotransferases)IBA
04/2002
1Platinum Compounds (Compounds, Platinum)IBA
11/2001
1Estrogen Receptor Modulators (Antiestrogen)IBA
09/2000
1Pharmaceutical PreparationsIBA
02/2000

Therapy/Procedure

15Drug Therapy (Chemotherapy)
11/2015 - 02/2000
9Therapeutics
01/2018 - 02/2000
2Breast Implants (Breast Implant)
12/2019 - 04/2019
2Adjuvant Chemotherapy
09/2013 - 02/2004
1Oral Administration
11/2015
1Radiotherapy
07/2015
1Contraindications
11/2003